Dr. Chris Sheldon is among the best biopharma dealmakers, and his impressive track record includes AstraZeneca/Daiichi’s ~$13bn partnership of DS8201 and Dato-Dxd, AstraZeneca’s $6.4b acquisition of Acerta over its Acalabrutinib, which is included in the sensation book “In Blood and Money”, during his time at AstraZeneca as the head of Oncology BD. Shortly after he took the helm of the GSK’s BD, he led the $2B acquisition of Bellus Health and also closed the deal with WuXi Biologics over their multiple bi- & multi-specific T cell engagers for oncology.